-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Category Archives: Clinics
Cytarabine for Injection 1 gm vial Bedford Labs Recall
Cytarabine for Injection, 1 gm/vial [Bedford Labs]: Recall: Risk of Lack of Sterility ISSUE: Bedford Laboratories announced a nationwide recall of three lots of cytarabine for injection—2066986, 2111675, and 2131148—because vials have a potential risk of a lack of sterility. The risk … Continue reading
Posted in Clinics, Emergency Rooms, Family Practice, FDA 2012, FDA Recall
Tagged 1 gm vial, Bedford Labs, Clinics, Cytarabine for Injection, Cytarabine for Injection 1 gm vial Bedford Labs Recall, drug risks, Emergency Rooms, Family Practice, FDA recall, Hospitals, Pharmacy, physician offices, Recall
Comments Off
Phenylephrine HCl Injection USP 1% 5 mL Vial Recall
UPDATED 02/23/2012] Phenylephrine HCl Injection, USP, 1% 5 mL Vial, (Lot# 0693) recalled. AUDIENCE: Pharmacy ISSUE: Recall initiated because some vials exhibit translucent visible particles consistent with glass delamination. Potential adverse events after intravenous administration include damage to blood vessels … Continue reading
Posted in Clinics, Emergency Rooms, FDA 2012, Hospitals, Pharmacy
Tagged (Lot# 0693), 1% 5 mL Vial, American Regent, Clinics, drug risks, Emergency Rooms, fda, FDA recall, Home Health Care Agencies, Hospitals, Infusion Centers, Pharmacy, Phenylephrine HCl Injection, Recall, USP)
Comments Off